Viewing Study NCT03602495


Ignite Creation Date: 2025-12-24 @ 2:11 PM
Ignite Modification Date: 2026-01-04 @ 8:46 AM
Study NCT ID: NCT03602495
Status: TERMINATED
Last Update Posted: 2021-12-13
First Post: 2018-07-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module